Literature DB >> 23036246

Pharmacotherapy of pediatric HIV infection.

Natella Rakhmanina1, B Ryan Phelps.   

Abstract

The delivery of safe and effective antiretroviral therapy to children and adolescents is crucial to save the lives of millions of children worldwide. The immunologic response to human immunodeficiency infection is closely related to a child's development and creates age-specific parameters for the evaluation of therapeutic response to antiretroviral therapy. Similarly, the development and maturation of organ systems involved in drug absorption, distribution, metabolism, and elimination determines significant changes in the pharmacokinetics of antiretroviral drugs throughout childhood. The authors review the evolution in treatment of pediatric HIV from infancy through adolescence.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23036246      PMCID: PMC3465562          DOI: 10.1016/j.pcl.2012.07.009

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  86 in total

1.  Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.

Authors:  Sharon A Nachman; Jane C Lindsey; Jack Moye; Kenneth E Stanley; George M Johnson; Paul A Krogstad; Andrew A Wiznia
Journal:  Pediatr Infect Dis J       Date:  2005-04       Impact factor: 2.129

2.  Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2.

Authors:  Sihem Benaboud; Alain Pruvost; Patrick A Coffie; Didier K Ekouévi; Saïk Urien; Elise Arrivé; Stéphane Blanche; Frédéric Théodoro; Divine Avit; François Dabis; Jean-Marc Tréluyer; Déborah Hirt
Journal:  Antimicrob Agents Chemother       Date:  2010-12-20       Impact factor: 5.191

Review 3.  Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges.

Authors:  B Ryan Phelps; Natella Rakhmanina
Journal:  Paediatr Drugs       Date:  2011-06-01       Impact factor: 3.022

4.  Age-related differences in the pharmacokinetics of stavudine in 272 children from birth to 16 years: a population analysis.

Authors:  V Jullien; A Raïs; S Urien; J Dimet; C Delaugerre; M Bouillon-Pichault; E Rey; G Pons; S Blanche; J M Tréluyer
Journal:  Br J Clin Pharmacol       Date:  2007-02-26       Impact factor: 4.335

5.  Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.

Authors:  Grace McComsey; Nasreen Bhumbra; Jen-Fu Ma; Mobeen Rathore; Ana Alvarez
Journal:  Pediatrics       Date:  2003-03       Impact factor: 7.124

6.  Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women.

Authors: 
Journal:  J Acquir Immune Defic Syndr       Date:  2003-04-01       Impact factor: 3.731

7.  Better adherence with once-daily antiretroviral regimens: a meta-analysis.

Authors:  Jean-Jacques Parienti; David R Bangsberg; Renaud Verdon; Edward M Gardner
Journal:  Clin Infect Dis       Date:  2009-02-15       Impact factor: 9.079

8.  The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group.

Authors:  M J O'Sullivan; P J Boyer; G B Scott; W P Parks; S Weller; M R Blum; J Balsley; Y J Bryson
Journal:  Am J Obstet Gynecol       Date:  1993-05       Impact factor: 8.661

9.  Young people in the United Kingdom and Ireland with perinatally acquired HIV: the pediatric legacy for adult services.

Authors:  Caroline Foster; Ali Judd; Pat Tookey; Gareth Tudor-Williams; David Dunn; Delane Shingadia; Karina Butler; Mike Sharland; Di Gibb; Hermione Lyall
Journal:  AIDS Patient Care STDS       Date:  2009-03       Impact factor: 5.078

Review 10.  Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management.

Authors:  Jane M Simoni; Arianna Montgomery; Erin Martin; Michelle New; Penelope A Demas; Sohail Rana
Journal:  Pediatrics       Date:  2007-05-28       Impact factor: 7.124

View more
  2 in total

Review 1.  HIV-1 proteins, Tat and gp120, target the developing dopamine system.

Authors:  Sylvia Fitting; Rosemarie M Booze; Charles F Mactutus
Journal:  Curr HIV Res       Date:  2015       Impact factor: 1.581

2.  Trends in Diagnoses Among Hospitalizations of HIV-infected Children and Adolescents in the United States: 2003-2012.

Authors:  Stacey A Hurst; Alexander C Ewing; Sascha R Ellington; Athena P Kourtis
Journal:  Pediatr Infect Dis J       Date:  2017-10       Impact factor: 2.129

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.